Loading, Please Wait...

CST: 17/08/2019 12:51:11   

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of RMED, CTST, OMCL and KPTI

17 Days ago

CEDARHURST, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Ra Medical Systems, Inc. (NYSE: RMED)
Investors Affected: stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.

A class action has commenced on behalf of certain shareholders in Ra Medical Systems, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a  result,  the  Company  could  not  reasonably  assure  that  its  newly  hired  sales  personnel  were  adequately  experienced;  (4) as  a  result,  the  Company  would  suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process  could  not  reasonably  support  increased  catheter  production;  (6) as  a  result, the Company would suffer production delays; and (7) as a result of the foregoing,   Defendants’   positive   statements   about   the   Company’s   business,   operations,  and  prospects,  were  materially  misleading  and/or  lacked  a  reasonable  basis.

Shareholders may find more information at https://kclasslaw.com/securities/ra-medical-systems-inc-loss-submission-form/?wire=3 

CannTrust Holdings Inc. (NYSE: CTST)
Investors Affected: November 14, 2018 - July 12, 2019

A class action has commenced on behalf of certain shareholders in CannTrust Holdings Inc. According to filed complaints, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/canntrust-holdings-inc-loss-submission-form/?wire=3 

Omnicell, Inc. (NASDAQGS: OMCL)
Investors Affected: October 25, 2018 - July 11, 2019

A class action has commenced on behalf of certain shareholders in Omnicell, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/omnicell-inc-loss-submission-form/?wire=3 

Karyopharm Therapeutics Inc (NASDAQGS: KPTI)
Investors Affected: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.

A class action has commenced on behalf of certain shareholders in Karyopharm Therapeutics Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Shareholders may find more information at https://kclasslaw.com/securities/karyopharm-therapeutics-inc-loss-submission-form/?wire=3 

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com 
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

Is your business listed correctly on America’s largest city directory network of 1,000 portals?